Swiss firm Mymetics is getting a boost from the Bill and Melinda Gates Foundation to conduct a key animal study for its HIV vaccine candidate at the Texas Biomedical Research Institute.
In an effort to better understand a certain disease-causing enzyme, British researchers have created a "map" of more than 100 proteins this enzyme is known to affect. They then identified a druglike molecule that blocks this enzyme to preserve these essential proteins.
Scientists have figured out how an emerging class of antibiotics binds to the bacterium that causes tuberculosis--a discovery that could lead to new therapeutics to fight the disease, which is becoming resistant to commonly used antimicrobials in many parts of the world.
As the ongoing Ebola outbreak in West Africa worsens, small and large companies alike are touting their investigational drugs in response to the World Health Organization's appeal to speed up research and development in the field.
Northwestern University researchers have developed the first animal model for dementia associated with amyotrophic lateral sclerosis.
A new sheds light on three different factors that may have contributed to ridding HIV from the "Berlin patient."
Conventional drug testing methods for cancer drugs are often unreliable. In vitro studies don't replicate the complex microenvironment surrounding tumors accurately, and oftentimes, animal research doesn't accurately show how therapies might work in people.
As antibiotic resistance rises, doctors are running out of effective drugs to treat patients with life-threatening bacterial infections. MIT engineers have a new possible way to combat superbugs: a gene-editing method called CRISPR that can disable any target gene.
A newly discovered genetic "switch" may be able to prompt cell division, a process that naturally slows down over a person's lifetime, in old age to help preserve organs and tissues.
Researchers may have found the key to destroying the amyloid-β clumps long associated with Alzheimer's disease, which could spur new approaches to drug discovery in a field that has seen more than its share of failures.
Japan's Global Health Initiative Technology Fund is investing $15.3 million to speed the development of new drugs and vaccines for malaria, dengue and Chagas disease.
Scientists at the New York University Langone Medical Center have developed a new technique that uses three familiar compounds, including vitamin C, to generate adult stem cells into pluripotent stem cells at a dramatically more efficient rate--more than 20-fold compared to the current method.
Scientists have discovered a natural antibiotic within a community of bacteria in the vagina, a finding that could point the way toward other human therapeutics.
A new class of compounds discovered by investigators at the University of Texas Southwestern Medical Center that could treat a range of neurodegenerative disorders has caught the eye of Google's new biotechnology venture Calico.
Pharma companies are increasingly relying on academic and nonprofit collaborations for basic science and drug discovery research, and some big players have formed some notable unions in 2014.
Researchers have pinpointed a small protein that may offer protection against bone loss associated with arthritis, a discovery that could lead to new treatments for the condition, which affects nearly one in 5 Americans.
The Geneva Foundation, along with partner BioFactura, received a grant of more than $3 million from the U.S. National Institutes of Health to develop an antibody drug to combat the Sudan strain of the ebolavirus.
The U.S. National Institutes of Health is launching a 6-year, $64 million program that will catalog human cell responses to drugs and genetic factors with the goal of aiding the development of new therapies for a range of diseases.
European and Japanese scientists have figured out how to "reset" human pluripotent stem cells, turning back the clock on cells so that they revert to their original state at the height of their development potential.
The U.S. government hasn't seen the last of its laboratory safety woes. Following a handful of accidents involving the mismanagement of highly infectious pathogens at federal facilities in recent months, the National Institutes of Health revealed on Sept. 5 that it uncovered small amounts of other improperly stored pathogens--including the toxin ricin and plague-causing bacteria.